Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 335-345 , June 2009

Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus

  • Debabrata Mukherjee, MD, FACC, FICA, FSVMB, Professor

      Affiliations

    • Corresponding Author InformationTel.: +1 859 323 5630; Fax: +1 859 323 6475.

References 

  1. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. Journal of the American College of Cardiology. 2006;47:921–929
  2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. The Journal of the American Medical Association. 2002;287:2570–2581
  3. Brun E, Nelson RG, Bennett PH, et al. Diabetes duration and cause-specific mortality in the Verona Diabetes Study. Diabetes Care. 2000;23:1119–1123
  4. Watson KE, Peters Harmel AL, Matson G. Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance. Journal of Cardiovascular Pharmacology and Therapeutics. 2003;8:253–260
  5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. The Journal of the American Medical Association. 2001;286:1317–1324
  6. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation. 1995;91:1472–1479
  7. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Annals of Internal Medicine. 2004;141:421–431
  8. Jude EB, Oyibo SO, Chalmers N, et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care. 2001;24:1433–1437
  9. Mozes G, Keresztury G, Kadar A, et al. Atherosclerosis in amputated legs of patients with and without diabetes mellitus. International Angiology. 1998;17:282–286
  10. Everhart JE, Pettitt DJ, Knowler WC, et al. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia. 1988;31:16–23
  11. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. The New England Journal of Medicine. 2001;344:1608–1621
  12. Brooks B, Dean R, Patel S, et al. TBI or not TBI: that is the question. Is it better to measure toe pressure than ankle pressure in diabetic patients?. Diabetic Medicine. 2001;18:528–532
  13. Young MJ, Adams JE, Anderson GF, et al. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia. 1993;36:615–621
  14. Ballard JL, Eke CC, Bunt TJ, et al. A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. Journal of Vascular Surgery. 1995;22:485–490discussion 490–482
  15. Hiatt WR, Jones DN. The role of hemodynamics and duplex ultrasound in the diagnosis of peripheral arterial disease. Current Opinion in Cardiology. 1992;7:805–810
  16. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Journal of the American College of Cardiology. 2006;47:1239–1312
  17. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England Journal of Medicine. 2003;348:383–393
  18. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. The American Journal of Cardiology. 1995;75:894–903
  19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  20. Standards of medical care in diabetes. Diabetes Care. 2008;31(Suppl. 1):S12–S54
  21. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. Journal of Internal Medicine. 2002;251:193–206
  22. Mukherjee D, Yadav JS. Update on peripheral vascular diseases: from smoking cessation to stenting. Cleveland Clinic Journal of Medicine. 2001;68:723–733
  23. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for claudication. The New England Journal of Medicine. 2002;347:1941–1951
  24. Angelkort B, Spurk P, Habbaba A, et al. Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology. 1985;36:285–292
  25. Jackson MR, Clagett GP. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 2001;119:283S–299S
  26. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678–686
  27. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Journal of Vascular Surgery. 1998;27:267–274discussion 274–265
  28. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. The American Journal of Medicine. 2000;109:523–530
  29. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery. 2000;31:S1–S296
  30. Stokes KR, Strunk HM, Campbell DR, et al. Five-year results of iliac and femoropopliteal angioplasty in diabetic patients. Radiology. 1990;174:977–982
  31. Spence LD, Hartnell GG, Reinking G, et al. Diabetic versus nondiabetic limb-threatening ischemia: outcome of percutaneous iliac intervention. American Journal of Roentgenology. 1999;172:1335–1341
  32. Clark TW, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. Journal of Vascular and Interventional Radiology. 2001;12:923–933
  33. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke?. American Journal of Epidemiology. 1988;128:116–123
  34. Rodriguez BL, D'Agostino R, Abbott RD, et al. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke; a Journal of Cerebral Circulation. 2002;33:230–236
  35. Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke; a Journal of Cerebral Circulation. 1996;27:210–215
  36. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke; a Journal of Cerebral Circulation. 1991;22:312–318
  37. Lehto S, Ronnemaa T, Pyorala K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke; a Journal of Cerebral Circulation. 1996;27:63–68
  38. Adams HP, Putman SF, Kassell NF, et al. Prevalence of diabetes mellitus among patients with subarachnoid hemorrhage. Archives of Neurology. 1984;41:1033–1035
  39. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  40. Rohr J, Kittner S, Feeser B, et al. Traditional risk factors and ischemic stroke in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Archives of Neurology. 1996;53:603–607
  41. Hankey GJ, Jamrozik K, Broadhurst RJ, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke; a Journal of Cerebral Circulation. 1998;29:2491–2500
  42. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. American Journal of Epidemiology. 2001;154:635–641
  43. Kushner M, Nencini P, Reivich M, et al. Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome. Annals of Neurology. 1990;28:129–135
  44. Fuller JH, Stevens LK, Wang SL. International variations in cardiovascular mortality associated with diabetes mellitus: the WHO Multinational Study of Vascular Disease in Diabetes. Annals of Medicine. 1996;28:319–322
  45. Tuomilehto J, Borch-Johnsen K, Molarius A, et al. Incidence of cardiovascular disease in Type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia. 1998;41:784–790
  46. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ (Clinical research ed). 2003;327:1267
  47. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355:253–259
  48. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041
  49. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004–1010
  50. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The Journal of the American Medical Association. 2002;288:2981–2997
  51. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  52. Colwell JA. Aspirin therapy in diabetes. Diabetes Care. 1997;20:1767–1771
  53. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of the Neurological Sciences. 1996;143:1–13
  54. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331–337
  55. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke; a Journal of Cerebral Circulation. 2001;32:280–299
  56. Tu JV, Wang H, Bowyer B, et al. Risk factors for death or stroke after carotid endarterectomy: observations from the Ontario Carotid Endarterectomy Registry. Stroke; a Journal of Cerebral Circulation. 2003;34:2568–2573
  57. Ballotta E, Da Giau G, Renon L. Is diabetes mellitus a risk factor for carotid endarterectomy? A prospective study. Surgery. 2001;129:146–152
  58. Pistolese GR, Appolloni A, Ronchey S, et al. Carotid endarterectomy in diabetic patients. Journal of Vascular Surgery. 2001;33:148–154
  59. Gurm HS, Yadav JS, Fayad P, et al. Long-term results of carotid stenting versus endarterectomy in high-risk patients. The New England Journal of Medicine. 2008;358:1572–1579
  60. Hack W, Kaste M, Bogousslavsky J, et al. European stroke initiative recommendations for Stroke Management-update 2003. Cerebrovascular Diseases (Basel, Switzerland). 2003;16:311–337
  61. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal. 2007;9(Supp C):C3–C74

PII: S1521-690X(08)00145-0

doi: 10.1016/j.beem.2008.10.015

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 3 , Pages 335-345 , June 2009

Article Tools

* Image Usage & Resolution